Mono and Polyubiquitylated Conjugates mAb (clone FK2)

Ubiquitin Conjugate Antibody

Cat. No. **68-0121-500**
Lot. No. **30124**

Quantity: 500 µg
Storage: -20˚C

FOR RESEARCH USE ONLY

NOT FOR USE IN HUMANS

CERTIFICATE OF ANALYSIS Page 1 of 1

Description

The anti-mono and polyubiquitylated conjugates mAb (FK2) demonstrate specific recognition of polyubiquitylated and monoubiquitylated proteins but shows no reactivity with free ubiquitin (Fujimoro *et al.* 1994). The anti-mono and polyubiquitylated conjugates mAb (FK2) has been extensively characterised and used not only to investigate ubiquitin chain formation on poly and mono ubiquitylated proteins by Western blotting but also in the detection of intracellular polyubiquitin chains in immunoassays (Takada *et al.* 1995; Fujimoro *et al.* 2005).

References:

Fujimuro M, Sawada H, Yokosawa H (1994) Production and characterization of monoclonal antibodies specific to multi-ubiquitin chains of polyubiquitinated proteins. *FEBS Lett* **349** 173-180.

Takada K, Nasu H, Hibi N, Tsukada Y, Ohkawa K, Fujimuro M, Sawada H, Yokosawa H (1995) Immunoassay for the quantification of intracellular multi-ubiquitin chains. *Eur J Biochem* **233** 42-47.

Fujimuro M, Yokosawa H (2005) Production of antipolyubiquitin monoclonal antibodies and their use for characterization and isolation of polyubiquitinated proteins. *Methods Enzymol* **399** 75-86.

Physical Characteristics

Clone: FK2

Isotype: IgM

Specificity: Recognises mono and polyubiquitylated conjugates. Does not cross-react with free ubiquitin.

Molecular Weight: ~150 kDa

Immunogen: Crude preparation of polyubiquitylated lysozyme

Source/Host: BALB/c mouse implantation ascites

Quantity: 500 µg

Concentration: 1 mg/ml

Formulation: 10 mM phosphate buffer, 0.15 M NaCl pH 7.4, 0.1% sodium azide

Stability/Storage: 12 months at -20˚C; aliquot as required

Quality Assurance

Anti-Mono and Polyubiquitylated Conjugates mAb (FK2) Antibody Activity Assay: By Western blotting the specific recognition of mono and poly-ubiquitylated conjugates by the antibody over free ubiquitin was demonstrated (Figure 1).

A priming and extension assay was run containing, UBE1 [6His-tagged] (Cat# 61-0001), UBE2W [6His-tagged] (Cat# 62-0085), UBE2N [untagged] (Cat# 62-0047), UBE2V1 [untagged] (Cat# 62-0059), Ubiquitin (Cat# 60-0001), CHIP [untagged] (Cat# 63-0003) and ATP. Using the anti-mono and polyubiquitylated conjugates mAb (FK2) antibody, detection of polyubiquitin chains extending from mono-ubiquitylated CHIP (Lane 1) and free chains generated by UBE2N/UBE2V1 in the presence of CHIP (Lane 3) were observed. In the absence of CHIP, detection of free polyubiquitin chains generated by UBE2N/UBE2V1 (Lanes 5 and 7) and ubiquitylated E2 enzymes (Lanes 5 and 6) was observed (Figure 2).



Figure 1



Figure 2

UBIQUIGENT™
www.ubiquigent.com
Dundee, Scotland, UK

ORDERS / SALES SUPPORT
International: +1-617-245-0020
US Toll-Free: 1-888-4E1E2E3 (1-888-431-3233)
Email: sales.support@ubiquigent.com

UK HQ and TECHNICAL SUPPORT
International: +44 (0) 1382 381147 (9AM-5PM UTC)
US/Canada: +1-617-245-0020 (9AM-5PM UTC)
Email: tech.support@ubiquigent.com

Email **services@ubiquigent.com** for enquiries regarding compound profiling and/or custom assay development services.

Lot-specific COA version tracker: v1.0.1